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OBJECTIVE—Pyruvate dehydrogenase complex (PDC) serves
as the metabolic switch between glucose and fatty acid utiliza-
tion. PDC activity is inhibited by PDC kinase (PDK). PDC shares
the same substrate, i.e., pyruvate, as glyceroneogenesis, a path-
way controlling fatty acid release from white adipose tissue
(WAT). Thiazolidinediones activate glyceroneogenesis. We stud-
ied the regulation by rosiglitazone of PDK2 and PDK4 isoforms
and tested the hypothesis that glyceroneogenesis could be con-
trolled by PDK.
RESEARCH DESIGN AND METHODS—Rosiglitazone was
administered to Zucker fa/fa rats, and then PDK4 and PDK2
mRNAs were examined in subcutaneous, periepididymal, and
retroperitoneal WAT, liver, and muscle by real-time RT-PCR.
Cultured WAT explants from humans and rats and 3T3-F442A
adipocytes were rosiglitazone-treated before analyses of PDK2
and PDK4 mRNA and protein. Small interfering RNA (siRNA)
was transfected by electroporation. Glyceroneogenesis was de-
termined using [1-
14C]pyruvate incorporation into lipids.
RESULTS—Rosiglitazone increased PDK4 mRNA in all WAT
depots but not in liver and muscle. PDK2 transcript was not
affected. This isoform selectivity was also found in ex vivo–
treated explants. In 3T3-F442A adipocytes, Pdk4 expression was
strongly and selectively induced by rosiglitazone in a direct and
transcriptional manner, with a concentration required for half-
maximal effect at 1 nmol/l. The use of dichloroacetic acid or
leelamine, two PDK inhibitors, or a speciﬁc PDK4 siRNA dem-
onstrated that PDK4 participated in glyceroneogenesis, therefore
altering nonesteriﬁed fatty acid release in both basal and rosigli-
tazone-activated conditions.
CONCLUSIONS—These data show that PDK4 upregulation in
adipocytes participates in the hypolipidemic effect of thiazo-
lidinediones through modulation of glyceroneogenesis. Diabetes
57:2272–2279, 2008
I
nsulin resistance is associated with alterations in the
balance between glucose and fatty acid oxidative
pathways. This leads to chronic hyperglycemia be-
cause of an excessive hepatic glucose production
(gluconeogenesis) (1) associated with a decrease in insu-
lin-induced glucose disposal within peripheral tissues,
such as skeletal muscle (2). Furthermore, insulin resis-
tance is associated with an excessive plasma concentra-
tion of nonesteriﬁed fatty acids (NEFAs), which is partly
due to a reduction of the antilipolytic action of insulin on
white adipose tissue (WAT) in postprandial situation and a
decrease in fatty acid reesteriﬁcation during lipolysis at
fast (3,4). Numerous lines of evidence support the notion
that this increase in plasma NEFA plays a pivotal role in
the early onset of insulin resistance (5–7). The mitochon-
drial pyruvate dehydrogenase complex (PDC) catalyzes
the irreversible decarboxylation of pyruvate to acetyl-CoA
and CO2. This complex regulates the balance between
oxidation of glucose and lipids, depending on nutritional
status, and thus plays the role of metabolic switch for fuel
selection (8). PDC activity is tightly controlled in the short
term by a continuous phosphorylation-dephosphorylation
cycle (9,10). Phosphorylation of the E1 subunit of PDC is
catalyzed by the PDC kinases (PDKs), which inactivate
PDC, while PDC phosphatases (PDPs) activate PDC
through dephosphorylation. Thus, the relative activities of
PDK and PDP regulate the proportion of PDC in the active
dephosphorylated form in mitochondria. Four isoforms of
PDK (PDK1–4) and two isoforms of PDP (PDP1 and -2)
have been described in mammals and are expressed in
varying amounts in a tissue-speciﬁc manner (11,12). To
prevent hyperglycemia in insulin-resistant states, inhibi-
tors of PDK have been developed to activate PDC, thereby
decreasing gluconeogenesis in liver and increasing glucose
oxidative capacities in skeletal muscle (13,14). However,
the role of PDC and its regulation by PDK-to-PDP ratio in
other insulin-sensitive tissues, like adipose tissue, has not
been extensively studied.
In WAT, lipolytic and reesteriﬁcation pathways are
active and both participate in the control of NEFA release
(15). Reesteriﬁcation into triglycerides of an important
part of NEFA arising from lipolysis requires the synthesis
of glycerol-3-phosphate (G3P), which mainly arises from
noncarbohydrate substrates like lactate or pyruvate
through a pathway named glyceroneogenesis (16,17). The
key enzyme of this metabolic pathway is the cytosolic
isoform of PEPCK-C (18). Pyruvate can be either carbox-
ylated to oxaloacetate by pyruvate carboxylase and used
for glyceroneogenesis or decarboxylated to acetyl-CoA by
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sized that pyruvate ﬂux through glyceroneogenesis was
negatively linked to PDC activity. As a consequence, the
PDK-to-PDP ratio would participate in the fatty acid
reesteriﬁcation pathway in adipocytes.
We have previously shown that adipocyte PEPCK-C and
the whole glyceroneogenic pathway are acute targets for
peroxisome proliferator–activated receptor (PPAR) ago-
nists, such as thiazolidinediones, in rodents and humans
(19–21). Pck1, which encodes PEPCK-C, is the earliest and
strongest rosiglitazone-activated gene in adipocytes, sug-
gesting an essential role of PEPCK-C in the response of
WAT to thiazolidinediones. Such an increase in PEPCK-C
precedes activation of glyceroneogenesis, which partici-
pates in the sequestration of lipids in adipose tissue
observed with these compounds and thus explains, at least
in part, the hypolipidemic properties of this class of drugs
(22). Because the inactivation of PDC by phosphorylation
could favor glyceroneogenesis, we have studied the regu-
lation by thiazolidinediones of the expression of PDK2 and
PDK4, the two isoforms of PDK expressed in adipose
tissue (11).
Here, we make the original demonstration of a rapid
tissue- and isoform-selective upregulation by rosiglitazone
of the expression of Pdk4 in adipocytes. We also demon-
strate the implication of PDK4 in the control of glycero-
neogenesis, suggesting that this upregulation participates
in the thiazolidinedione-induced decrease in NEFA release
from WAT.
RESEARCH DESIGN AND METHODS
Dulbecco modiﬁed Eagle’s medium (DMEM) was from Life Technologies
(Cercy-Pontoise, France). Rosiglitazone was from Alexis Biochemicals
(Coger, Paris). Leelamine was from Cayman Chemicals (Interchim, Montlu-
c ¸on, France). Small interfering RNA (siRNA) was from Invitrogen (Carlsbad,
CA). Fetal bovine serum, essentially fatty acid–free BSA, 5,6-dichloro-1B-D-
ribofuranosyl benzimidazole (DRB), dichloroacetate (DCA), and all other
products were purchased from Sigma (L’isle d’Abeau Chesnes, France).
Male Zucker fa/fa rats were purchased from Charles River Laboratories
(L’arbresle, France), and male Sprague-Dawley rats were purchased from
Janvier Laboratories (Bagneux, France) at 6 weeks of age. They were allowed
to acclimate 2 weeks before initiation of treatment and were kept on a 12-h
light/dark cycle at constant room temperature. Conventional laboratory diet
and tap water were provided ad libitum. In vivo experiments with Zucker rats
were carried out as previously described (21). Brieﬂy, rats were given a dose
o f5m g kg
1  day
1 rosiglitazone (maleate) or vehicle (0.5% methylcellulose)
via oral gavage in the morning. Four rats were used per treatment group. After
4 days of treatment, animals were fasted during 4 h before killing. Plasma
samples were obtained via the jugular vein, and aliquots were stored at 20°C
for further glucose (Accu-Check; Roche, Meylan, France), insulin (Ultrasen-
sitive rat insulin ELISA; EuroBio, Courtaboeuf, France), triglycerides (Vitros
chemistry system; Johnson & Johnson), and NEFA (Fatty Acids half micro
test; Roche) determinations. Samples of subcutaneous, periepididymal, and
retroperitoneal WAT, liver, and soleus muscle were dissected and rapidly
frozen in liquid nitrogen and stored at 80°C for further RNA analysis. The
protocol for the animal studies was conducted according to the French
Guidelines for the Care and Use of Experimental Animals.
Culture of human adipose tissue explants. Explants of subcutaneous WAT
were obtained from eight women undergoing elective surgery. They were aged
45.7  4.4 (mean  SE) and had BMI of 30.29  1.42 kg/m
2. None of the
subjects suffered from known metabolic or malignant diseases or were taking
medications known to alter adipocyte metabolism. The study was performed
according to the Declaration of Helsinki. All the patients gave informed
written consent.
WAT specimen from the subcutaneous region was obtained within 15 min
after the onset of surgery. WAT (300 mg) was cut in small fragments of 20
mg and cultured in DMEM containing 12.5 mmol/l glucose, 200 IU/ml
penicillin, and 50 mg/l streptomycin at 37°C in 10% CO2 atmosphere. After 1 h
of preincubation, rosiglitazone was added for 5 h. Explants were then frozen
in liquid nitrogen before RNA extraction.
Isolation of adipocytes. Adipocytes from Sprague-Dawley rat periepididy-
mal fat pads were isolated in DMEM containing 5 mmol/l glucose, 0.5 mmol/l
pyruvate, and 2% BSA, as described by Weisberg et al. (23). The pellet
containing stromavascular fraction was discarded, whereas the ﬂoating cells
were collected as adipocyte-enriched fraction.
Cell culture and treatment. 3T3-F442A adipocytes were cultured at 37°C in
a humidiﬁed atmosphere of 10% CO2 in DMEM containing 25 mmol/l glucose,
10% newborn calf serum, 200 IU/ml penicillin, 50 mg/l streptomycin, 8 mg/l
biotin, and 4 mg/l pantothenate. At conﬂuence, the medium was changed to
DMEM supplemented with 10% FCS and 20 nmol/l insulin to promote
adipogenesis. This medium was changed every 2–3 days for 6 days. Twenty-
four hours before RNA extraction, cells were placed in serum-free and
hormone-free medium.
RNA interference. RNA interference with siRNA was performed by electro-
poration according to the manufacturer (Cell line Nucleofector kit L; Amaxa).
Brieﬂy, 3T3-F442A adipocytes on day 8 of differentiation were detached from
culture dishes with trypsin-EDTA (Invitrogen). Tubes containing about 2
million cells were centrifuged for 10 min at 127g. Pelleted cells were then
resuspended in 100 l Nucleofector solution. Control (5-GGAGGUGGUU
GACUUUCAUTT; Invitrogen) or murine PDK4-speciﬁc (5-GGAUUUGGUG
GAGUUCCAUTT, Invitrogen) siRNAs were delivered into adipocytes (250
nmol/l) by electroporation. Transfection was stopped by adding DMEM
containing 10% FCS. Adipocytes were then reseeded into six-well plates.
Twenty-four hours after electroporation, medium was changed to FCS-free
DMEM containing rosiglitazone or not. Nineteen hours later, cells were used
for RNA analysis or metabolic studies.
RNA analysis. Total RNA was extracted from the cell lines and from rat WAT
by the method of Chomczynski and Sacchi (24), whereas RNeasy total RNA kit
from Qiagen (Courtaboeuf, France) was used for human WAT explants.
Sample quality was controlled by 260:280 nm absorption ratio determination
(between 1.8 and 2.0).
For real-time RT-PCR analyses, 1.25 g total RNA was ﬁrst reverse
transcribed using the High Capacity cDNA Archive kit (Applied Biosystems,
Courtaboeuf, France). Reverse transcribed RNA were ampliﬁed on a thermal
cycler (ABI prism 7900 HT; Applied Biosystems) using the SYBR green
ﬂuorescence method and speciﬁc oligonucleotides. Results were analyzed
with the SDS 2.1 real-time detection system software. Quantiﬁcation of RNA
was carried out by comparison of the number of cycles required to reach
reference and target threshold values (- Ct method).
Protein analysis. Mitochondrial fraction was prepared from 3T3-F442A
adipocytes, and mitochondrial pellet was resuspended in PBS 1 buffer,
containing 1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% SDS to
extract mitochondrial proteins. Protein concentrations were determined using
the Bradford method using BSA as the standard. Fractions (50 g) were
subjected to SDS-PAGE using a 10% resolving gel with a 6% stacking gel.
Resolved proteins were transferred electrophoretically to nitrocellulose mem-
branes, blocked for1ha t22°C with Tris-buffered saline (TBS) supplemented
with 5% (w/v) nonfat powdered milk and incubated overnight at 4°C with
polyclonal antisera raised against mouse PDK4, PDK2 from Santa Cruz
Biotechnology (Tebu-bio, France), or PDC-E2 (provided by Dr. J.G. Lindsay,
University of Glasgow, U.K.). Nitrocellulose membranes were then washed
with 1% Tween in TBS (three times for 5 min) and incubated with horseradish
peroxidase–linked secondary antibody anti-rabbit IgG (1:5,000 dilution, in 1%
[w/v] BSA in TBS with 0.05% Tween) for1ha t22°C. Bound antibody was
visualized using ECL according to the manufacturer’s instructions. The blots
were exposed to Hyperﬁlm, and the signals were quantiﬁed by scanning
densitometry.
Metabolic studies. Isolated adipocytes were submitted to incorporation
assay immediately after their collection. [1-
14C]pyruvate incorporation was
performed with 400 l adipocyte suspension in 2 ml Krebs buffer containing
2% fatty acid–free BSA, 0.5 mmol/l pyruvate, and [1-
14C]pyruvate at isotopic
dilution of 25. When indicated, PDK inhibitors were added in the incorpora-
tion medium. Untransfected or siRNA-transfected 3T3-F442A adipocytes were
treated or not for 18 h with rosiglitazone. Three hours before [1-
14C]pyruvate
incorporation, medium was replaced with glucose-free, serum-deprived
DMEM containing 0.3% free fatty acid BSA. Pyruvate incorporation was
carried out with 20 mol/l [1-
14C]pyruvate in Krebs buffer containing 0.3% BSA
and leelamine, when indicated. After a 2-h incubation, cells were rinsed in PBS
and scraped in 10 mmol/l Tris-Cl, pH 7.4, containing 0.25 mol/l sucrose, 0.1
mmol/l EDTA, 0.1 mmol/l dithiothreitol, and 0.1% Triton and frozen in liquid
nitrogen before lipid extraction. Lipids were extracted according to the
simpliﬁed method of Bligh and Dyer (25), and the subsequent [1-
14C]pyruvate
incorporation was estimated by counting the radioactivity associated with the
chloroformic fraction. NEFA concentration was monitored in the incubation
medium. Under each conditions, cells were submitted to a test of toxicity,
using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT)
method, which did not show any drug-induced toxicity.
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functional PDK assay was performed using a commercially available PDC
puriﬁed from pig heart and containing intrinsic PDK activity, as extensively
described by Jackson et al. (26), with 800 g/ml puriﬁed PDC.
Image quantiﬁcation and data analysis. Quantitative results of Western
blotting were obtained by densitometry in ImageJ software. The nonparamet-
ric Mann-Whitney U test for pairwise comparisons was applied due to the
small number of experiments. Analyses were performed using the StatView
4.01 (Abacus Concepts, Berkeley, CA) statistical package. A value of P 	 0.05
was considered statistically signiﬁcant.
RESULTS
Rosiglitazone induces Pdk4 expression in adipose
tissue and in adipocytes. We showed previously that
treating male Zucker fa/fa rats with rosiglitazone for 4
days signiﬁcantly lowered both plasma insulin and serum
lipid levels (21). This normalization in lipidemia was
linked to a large induction in WAT glyceroneogenesis, thus
decreasing NEFA release. Under these conditions, the
expression of one of the key genes involved in glyceroneo-
genesis, PEPCK-C, was stimulated two- to threefold in
subcutaneous, periepididymal, and retroperitoneal WAT.
A similar rosiglitazone-induced normalization in lipidemia
was obtained in the present study (Table 1). We used
real-time RT-PCR to analyze the effect that rosiglitazone
would have on the expression of Pdk2, Pdk4, Pdp1, and
Pdp2 in the same three WAT depots. PDP1 and PDP2
mRNAs remained unaffected by rosiglitazone treatment
(data not shown). In contrast, rosiglitazone induced a
large 3- to 4.5-fold increase in PDK4 mRNA in all depots
but neither in liver nor in soleus muscle, demonstrating a
tissue-speciﬁc response of this gene under this acute
treatment (Fig. 1A). In contrast, Pdk2 expression re-
mained insensitive to rosiglitazone whatever tissue, dem-
onstrating a selective action of the drug on PDK isoforms
(Fig. 1B).
To determine whether rosiglitazone acts on PDK4 gene
expression through a direct effect on WAT, we treated ex
vivo rats and humans WAT explants for 5 h with rosiglita-
zone and monitored PDK4 mRNA. Both species responded
to rosiglitazone by a large three- to fourfold increase in
Pdk4 expression, whereas mRNA concentrations of PDK2
and pyruvate carboxylase (PC) were unaffected (Fig. 2A
and B). WAT is a heterogeneous tissue containing not only
adipocytes but also many other cell types, including prea-
dipocytes, macrophages, ﬁbroblasts, and endothelial cells.
To study the mechanism of rosiglitazone action on Pdk4
gene expression in a homogeneous source of adipocytes,
we used the 3T3-F442A adipocyte cell line. These cells
were previously used to study Pdk1 regulation and glyc-
eroneogenesis by PPAR activators (27). A 2-h treatment
of differentiated 3T3-F442A adipocytes with rosiglitazone
induced PDK4 mRNA 2.5-fold whereas the concentrations
of PDK2 and PC mRNAs were unchanged (Fig. 2C). We
used Western blot experiments with speciﬁc antibodies for
either PDK2 or PDK4 to monitor the relative expression of
both protein isoforms in 3T3-F442A adipocytes at day 6
after conﬂuence. Taking PDC-E2 as a control, results
strongly suggest that PDK4 protein amount is about three-
fold that of PDK2 in adipocytes (Fig. 2D).
Rosiglitazone directly increases Pdk4 transcription
and protein abundance in 3T3-F442A adipocytes. Ros-
iglitazone induction in Pdk4 expression was acute, with a
maximum attained at2hi n3T3-F442A adipocytes (Fig.
3A). We chose this 2-h treatment to determine the rosigli-
tazone concentration that produced the half-maximal ef-
fect (EC50). Incubation of 3T3-F442A adipocytes with
rosiglitazone caused a dose-dependent increase in the
abundance of PDK4 mRNA (Fig. 3B). EC50 was at about 1
nmol/l, in agreement with the afﬁnity of rosiglitazone for
PPAR, strongly suggesting that this receptor was in-
volved. The rosiglitazone-induced increase in PDK4 mRNA
could be the result of stimulation of Pdk4 transcription
TABLE 1
Effect of rosiglitazone treatment on metabolic parameters in
male Zucker fa/fa rats
Control Rosiglitazone
Body wt (g) 323  14 324  10
Glucose (mg/dl) 120  21 153  35
Insulin (ng/dl) 8.8  0.6 2.7  0.4*
NEFA (mol/l) 180  70 60  30†
Triglycerides (mg/dl) 145  21.9 87.9  14.5†
Data are means  SE (n 
 4 for each group). Eight-week-old male
Zucker fa/fa rats were or were not treated with rosiglitazone (5 mg
 kg
1  day
1) for 4 days. Blood samples were collected for analyses.
*P 	 0.01, †P 	 0.05.
FIG. 1. Rosiglitazone induces PDK4 gene expression in fa/fa rat
adipose tissue in vivo. Male Zucker fa/fa rats were treated for 4 days
with rosiglitazone (5 mg  kg
1  day
1). Rats were killed, and tissues
were removed. Total RNA was extracted from subcutaneous, periepi-
didymal, and retroperitoneal WAT, liver, and soleus muscle. PDK4 (A)
and PDK2 (B) mRNA were analyzed by real-time RT-PCR. Values were
normalized to 18S rRNA and expressed as percentage of untreated
rats. Results are mean  SE from four rats in each group. *P < 0.05;
**P < 0.01; ***P < 0.001.
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DRB, a transcription inhibitor, and puromycin, a protein
synthesis inhibitor. 3T3-F442A adipocytes were ﬁrst
treated with 1 mol/l rosiglitazone with or without 80
mol/l DRB for 0.5–2 h before analyzing PDK4 mRNA
abundance by real-time RT-PCR. Whatever the time of
treatment, DRB abolished the induction of PDK4 mRNA by
rosiglitazone (Fig. 3A). Under the same conditions of
rosiglitazone treatment, puromycin had no effect, demon-
strating that de novo protein synthesis was not required
(data not shown). These results are strongly in favor of
rosiglitazone directly increasing transcription rate of
Pdk4. Second, we examined the possibility of a rosiglita-
zone-induced PDK4 mRNA stabilization by incubating
3T3-F442A adipocytes for 2 h with rosiglitazone and then
for various times with DRB before monitoring PDK4
mRNA abundance by real-time RT-PCR. In the absence of
rosiglitazone, PDK4 mRNA half-life was estimated at 1.5
h as previously obtained in other cell types (Fig. 3C). After
a 2-h treatment with 1 mol/l rosiglitazone, PDK4 mRNA
half-life rose to 2 h, showing a slight rosiglitazone-
induced stabilization of PDK4 messenger in adipocytes.
mRNA induction was followed by a signiﬁcant twofold
increase in PDK4 protein at 18 h of rosiglitazone treatment
(Fig. 3D).
Contribution of PDK4 to fatty acid reesteriﬁcation in
basal and rosiglitazone-treated adipocytes. To test the
potential involvement of PDC and PDK in the control of
pyruvate ﬂux toward glyceroneogenesis, pyruvate incor-
poration into neutral lipids was monitored in isolated
adipocytes in the presence or not of PDK inhibitors. We
tested both DCA, one of the few known highly speciﬁc
synthetic PDK inhibitor, and leelamine, a more recent PDK
inhibitor (28,29). Results of MTT test demonstrated that
neither of these compounds was cytotoxic at the concen-
trations used (data not shown). Figure 4A shows that both
inhibitors signiﬁcantly reduced glyceroneogenic ﬂux in
isolated adipocytes from rat WAT. However, the concen-
trations used to reach a statistical signiﬁcant reduction
differ for the two inhibitors. At 50 mol/l, leelamine
inhibited pyruvate incorporation by 40% (P 	 0.001),
whereas a 10-fold higher DCA concentration was required
to produce a signiﬁcant 60% inhibition (P 	 0.01) (Fig. 4A).
Hence, leelamine is more efﬁcient to reduce pyruvate
incorporation into triglycerides than DCA. To ensure that
leelamine effect was due to PDK inhibition, an in vitro
assay was performed, monitoring residual PDC activity
after kinase action. At the concentration of 50 mol/l,
leelamine induced an inhibition of 41.00  2.14% in PDK
activity (n 
 8, P 	 0.001).
To further study the functional involvement of PDK in
both basal and rosiglitazone-activated conditions, we
treated or not 3T3-F442A adipocytes with 1 mol/l rosigli-
tazone for 18 h and then monitored the incorporation of
[1-
14C]pyruvate into lipids in the presence or not of
leelamine for 2 h. The addition of 50 and 100 mol/l
leelamine reduced basal glyceroneogenic ﬂux 25 and 56%,
respectively, with a concomitant increase in NEFA release
(Fig. 4B and C). As expected, rosiglitazone induced glyc-
eroneogenesis and reduced NEFA release. The addition of
50 and 100 mol/l leelamine on rosiglitazone-pretreated
cells reduced glyceroneogenic ﬂux 59 and 115%, respec-
tively, with a concomitant increase in NEFA release (Fig.
4B and C). Under these conditions, glycerol release was
not modiﬁed (data not shown). Hence, PDK inhibitors did
not affect lipolysis. To ascertain the speciﬁc implication of
FIG. 2. Rosiglitazone induces Pdk4 expression in rat and human adipose
tissue ex vivo and in 3T3–F442A adipocytes. Rat periepididymal (A) and
human subcutaneous abdominal WAT (B) were cultured in DMEM con-
taining 12.5 mmol/l glucose and treated or not with 1 mol/l rosiglitazone
f o r5h .C: 3T3–F442A adipocytes at day 6 of differentiation were cultured
in DMEM containing 25 mmol/l glucose and treated or not for 2 h with 1
mol/l rosiglitazone. Total RNA was extracted, and PDK4, PDK2, and PC
mRNA were analyzed by real-time RT-PCR with normalization to glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) mRNA. D: Protein ex-
tracts were obtained from differentiated 3T3–F442A adipocytes and
subjected to Western blotting using antibodies against PDK4, PDK2, and
the E2 subunit of PDC complex. Data are means  SE from three to ﬁve
independent experiments, each performed in triplicate, and are ex-
pressed as percent of control. **P < 0.01.
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transfected in 3T3-F442A adipocytes. Forty-eight hours
after transfection, a speciﬁc 60% (P 	 0.001) decrease in
PDK4 mRNA was observed whereas concentrations in
PDK2, PDP1, PDP2, PC, and PEPCK-C mRNAs remained
unchanged (Fig. 5A). Furthermore, PDK4 siRNA did not
induce interferon (IFN)- mRNA, showing the lack of
IFN response (Fig. 5A). Incorporation of [1-
14C]pyruvate
into lipids was reduced 40% after transfection of adipo-
cytes with PDK4 siRNA (P 	 0.05) (Fig. 5B). Under
these experimental conditions, rosiglitazone induced
[1-
14C]pyruvate incorporation 3.1-fold in control cells
(P 	 0.001) (Fig. 5B). A 35% decrease in rosiglitazone-
induced [1-
14C]pyruvate incorporation was observed in
the presence of PDK4 siRNA (P 	 0.01).
DISCUSSION
For a better understanding of the early mechanisms in-
volved in PPAR effects in WAT, we investigated the
regulation of potent primary targets for thiazolidinediones.
One important observation of our present report is that the
expression of Pdk4 is acutely induced by the speciﬁc
PPAR agonist rosiglitazone in WAT explants from rats
and humans. Induction of PDK4 mRNA occurs in the same
time frame as that of PEPCK-C transcript. Furthermore, as
we observed previously for PEPCK-C, a 4-day administra-
tion of rosiglitazone to Zucker fa/fa rats, a model of insulin
resistance and dyslipidemia, induced an increase in Pdk4
expression speciﬁcally in WAT from several depots. A
longer term in vivo effect of COOH, a PPAR agonist, on
PDK4 mRNA was observed by Laplante et al. (30). Our
results are in accordance with these previous results in
which, however, the issue of tissue-speciﬁc action of the
drug was not addressed. In the course of our experiments,
we showed that rosiglitazone induction of Pdk4 expres-
sion was tissue-speciﬁc because liver and muscle did not
respond to such a treatment. Furthermore, in our study,
Pdk2 expression remained unaffected by rosiglitazone
treatment, whereas Laplante et al. (30) observed a simul-
taneous induction of both Pdk2 and Pdk4 expression in
visceral WAT, probably because of the longer duration of
treatment used (3 weeks). In contrast to our results, Way
FIG. 3. Mechanism of rosiglitazone stimulation of Pdk4 expression in 3T3–F442A adipocytes. Quantitative changes in the abundance of PDK4
mRNA in 3T3–F442A adipocytes either cultured for the indicated times with 1 mol/l rosiglitazone in the absence or in the presence of 80 mol/l
DRB (A) or treated for 2 h with the indicated concentrations of rosiglitazone (B). In C, 3T3–F442A adipocytes were treated or not with 1 mol/l
rosiglitazone for 2 h before DRB addition, and then mRNA for PDK4 was estimated over time. Values were normalized to GAPDH and are
expressed as percentage of control. In D,4 0g mitochondrial proteins from adipocytes treated or not with 1 mol/l rosiglitazone for 18 h were
subjected to Western blotting. Densitometry values were normalized to PDC-E2 and expressed as percentage of control. Results are means  SE
of three to ﬁve independent experiments, each performed in triplicate. *P < 0.05; **P < 0.01; ***P < 0.001.
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GW1929, a different PPAR agonist, reduced the concen-
tration of PDK4 transcript in muscles from ZDF Zucker
diabetic rats (31). One explanation for this discrepancy
could be that ZDF rats are insulin-resistant and diabetic at
earlier times than the Zucker fa/fa rats we used here.
Hence when ZDF rats are 9 weeks old, their insulin-
resistant state is correlated with low PDK4 activity in
muscle, which could be raised by rosiglitazone. Such an
effect is probably indirect as the result of thiazolidinedi-
one-induced rapid decrease in blood NEFA. In 8-week-old
fa/fa rats, blood NEFA concentrations are near to normal
and therefore unable to stimulate PDK4 in muscle (21).
Whatever happens in muscle, our data clearly demonstrate
that PDK4 is an early-responsive positive target for PPAR
in WAT.
To further study the mechanisms by which rosiglitazone
stimulates Pdk4 expression, we used the 3T3-F442A cell
line. Rosiglitazone rapidly stimulated Pdk4 expression in
fully differentiated 3T3-F442A adipocytes as previously
found in 7,800 C1 hepatoma cells treated with a PPAR
ligand (32). Using transcription and translation inhibitors,
we showed that PDK4 was a transcriptional and direct
target for rosiglitazone. Our results are in slight contrast
with those from Sears et al. (33) who showed that in
3T3-L1 adipocytes, rosiglitazone induction of PDK4 mRNA
is delayed, suggesting that in these cells, PDK4 is an
indirect PPAR target. Furthermore, we found that half-
life of the PDK4 transcript was short, i.e., 2h ,a s
previously observed for hepatoma cells (32). Interestingly,
PC gene expression was not modulated. PC was previ-
ously shown as a PPAR-induced gene during adipocyte
differentiation of the 3T3-L1 preadipocytes (34). Our ob-
servation that rosiglitazone does not modulate pyruvate
carboxylase gene expression in differentiated 3T3-F442A
adipocytes is in agreement with a delayed action of PPAR
agonist on this gene during adipocyte differentiation.
We show unambiguously here that PDK4 participates in
adipocyte glyceroneogenesis because leelamine, a PDK
inhibitor, and a speciﬁc PDK4 siRNA strongly reduces
basal and rosiglitazone-induced pyruvate incorporation
into neutral lipids, with a coordinated stimulation of NEFA
release. These results are illustrated in Fig. 6 in which
pyruvate crossroad is shown as the central switch for the
A
BC
FIG. 4. PDK4 inhibition alters basal and rosiglitazone-activated glyceroneogenesis. A: Using [1-
14C]pyruvate incorporation into neutral lipids,
glyceroneogenic ﬂux was monitored in isolated adipocytes from rat periepididymal fat pads for 2 h in the presence or not of PDK inhibitors,
leelamine, or DCA at the indicated concentrations. 3T3–F442A adipocytes were treated or not with 1 mol/l rosiglitazone for 18 h, and then
glyceroneogenic ﬂux (B) and medium NEFA concentration (C) were monitored in the presence or not of leelamine for 2 h. Results are means 
SE of three independent experiments, each performed in triplicate. **P < 0.01; ***P < 0.001 vs. control; §§§P < 0.001 vs. rosiglitazone treatment.
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circulating substrate for the whole process is lactate,
which is abundant in the blood under the physiological
situation during which lipolysis is activated, i.e., fasting.
Rosiglitazone induction of both PDK4 and PEPCK-C re-
sults, respectively, in reduction of pyruvate ﬂux toward
acetyl-CoA because PDC activity is strongly inhibited by
PDK4 and in increased G3P synthesis via PEPCK-C. Such
a combined action of thiazolidinediones allows increased
reesteriﬁcation during lipolysis leading to decreased
NEFA release from adipocytes. The reduced PDC activity
under rosiglitazone treatment raises the intriguing possi-
bility that thiazolidinediones may reduce glucose oxida-
tion to CO2 in adipocytes, in contrast with what occurs in
muscle and at the whole-body level. Although this issue
requires further development, we can emphasize here that
glucose oxidation is not a predominant pathway during
fasting and in the absence of insulin.
Elevated concentration of plasma NEFA is now recog-
nized as a key factor in the onset of insulin resistance and
type 2 diabetes (35). Our previous results indicate that
WAT glyceroneogenesis is important to lipid homeostasis
and that a disregulation in this pathway has profound
pathophysiological effects (19–21,36). This would result in
dramatic changes in net NEFA output, hence in the
concentration of plasma NEFA, which in turn would
mediate metabolic alterations, for instance by affecting
insulin sensitivity of peripheral tissues. Here, we provide
clear evidence that PDK4 is a new player in the glycero-
neogenic process and is a thiazolidinedione target selec-
tively in WAT. Therefore, by means of PEPCK-C and of
PDK4, glyceroneogenesis is a target for thiazolidinediones,
the antidiabetic action of which seems clearly to be linked
to their hypolipidemic effect (22,37).
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FIG. 5. Inﬂuence of PDK4 siRNA on gene expression and glyceroneo-
genesis in 3T3–F442A adipocytes. 3T3–F442A adipocytes were trans-
fected with a control or a PDK4-speciﬁc siRNA. Forty-eight hours after
transfection, cells were used for mRNA studies (A)o r[ 1 -
14C]pyruvate
incorporation experiments (B). A: Total RNA was extracted, and
concentration of PDK4, PDK2, PDP1, PDP2, pyruvate carboxylase,
PEPCK-C, and IFN- mRNA was analyzed by real-time RT-PCR with
normalization to 18S rRNA. Control or PDK4 siRNA-transfected adi-
pocytes were treated or not with 0.1 mol/l rosiglitazone for 18 h, and
glyceroneogenic ﬂux was monitored. Results are means  SE of three
independent experiments, each performed in triplicate. *P < 0.05,
**P < 0.01; ***P < 0.001 vs. control; §§P < 0.01 vs. rosiglitazone
treatment.
FIG. 6. Pyruvate routing for fatty acid reesteriﬁcation: inﬂuence of
thiazolidinediones. Pyruvate is either decarboxylated by PDC into
acetyl-CoA or carboxylated to oxaloacetate (OA) by PC in mitochon-
dria. Oxaloacetate is the precursor of G3P, and PEPCK-C is involved in
this process, allowing for reesteriﬁcation into triglyceride (TG) of
NEFA arising from lipolysis. This could lead to decreased NEFA
release in the blood ﬂow, without affecting glycerol release. PDC is
mainly regulated by a phosphorylation/dephosphorylation cycle. PDK4
inactivates PDC, thereby regulating pyruvate availability for glycero-
neogenesis in adipocytes. Rosiglitazone induces both PDK4 and
PEPCK-C, thereby reducing pyruvate ﬂux toward acetyl-CoA and
favoring G3P production.
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